Your browser is no longer supported. Please, upgrade your browser.
VRTX Vertex Pharmaceuticals Incorporated weekly Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E92.25 EPS (ttm)2.25 Insider Own0.10% Shs Outstand256.95M Perf Week5.68%
Market Cap53.21B Forward P/E31.41 EPS next Y6.59 Insider Trans-67.93% Shs Float256.80M Perf Month17.58%
Income583.80M PEG3.18 EPS next Q1.19 Inst Own97.50% Short Float1.60% Perf Quarter14.34%
Sales3.62B P/S14.70 EPS this Y99.10% Inst Trans-0.40% Short Ratio3.41 Perf Half Y21.66%
Book/sh20.45 P/B10.13 EPS next Y37.38% ROA31.40% Target Price228.00 Perf Year19.81%
Cash/sh15.55 P/C13.32 EPS next 5Y29.02% ROE44.00% 52W Range151.80 - 207.64 Perf YTD24.98%
Dividend- P/FCF39.03 EPS past 5Y23.90% ROI11.20% 52W High-0.41% Beta1.45
Dividend %- Quick Ratio3.30 Sales past 5Y20.30% Gross Margin86.60% 52W Low36.22% ATR4.35
Employees2500 Current Ratio3.40 Sales Q/Q21.10% Oper. Margin21.40% RSI (14)73.40 Volatility1.73% 2.44%
OptionableYes Debt/Eq0.11 EPS Q/Q-55.40% Profit Margin59.20% Rel Volume0.36 Prev Close207.10
ShortableYes LT Debt/Eq0.10 EarningsOct 30 AMC Payout0.00% Avg Volume1.21M Price206.78
Recom2.00 SMA206.09% SMA5013.75% SMA20015.26% Volume35,088 Change-0.15%
Nov-12-19Initiated SunTrust Buy $235
Oct-17-19Resumed BofA/Merrill Buy $220
Sep-03-19Upgrade Goldman Neutral → Buy $226 → $254
Aug-01-19Downgrade Needham Buy → Hold
May-23-19Resumed Citigroup Buy $205
May-21-19Initiated Credit Suisse Outperform $209
Apr-12-19Initiated Evercore ISI In-line
Mar-26-19Upgrade William Blair Mkt Perform → Outperform
Mar-19-19Downgrade SVB Leerink Outperform → Mkt Perform
Feb-06-19Downgrade Maxim Group Buy → Hold
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Oct-26-18Upgrade H.C. Wainwright Neutral → Buy $220
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Aug-07-18Reiterated Stifel Buy $182 → $200
Mar-05-18Reiterated Maxim Group Buy $195 → $200
Feb-13-18Reiterated JMP Securities Mkt Outperform $200 → $211
Feb-01-18Reiterated Barclays Overweight $180 → $200
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Sep-29-17Initiated BTIG Research Buy $200
Nov-13-19 02:32PM  Ex-Novartis exec named as Flagship's matchmaker for Big Pharma partnerships American City Business Journals
07:55AM  UPDATE 1-Vertex deal with Wales expands cystic fibrosis treatment coverage to all of UK Reuters
07:08AM  Vertex reaches deal with Wales for cystic fibrosis treatment Reuters
06:29AM  Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines Business Wire
Nov-12-19 10:56AM  FDA intervenes for 3rd time in Solid Biosciences' Duchenne drug tests American City Business Journals
10:51AM  Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines Business Wire
Nov-11-19 09:05AM  Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug Zacks
Nov-08-19 02:33PM  Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates Zacks
02:20PM  FDA approves Acceleron's blood disorder drug ahead of schedule American City Business Journals
08:56AM  Arena Pharmaceuticals' (ARNA) Q3 Loss Widens, Revenues Beat Zacks
08:34AM  Moving Average Crossover Alert: Vertex Pharmaceuticals Zacks
Nov-07-19 04:01PM  Vertex to Present at the Credit Suisse Healthcare Conference on November 12 Business Wire
11:04AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3 Zacks
10:46AM  Puma (PBYI) Q3 Earnings Beat, Nerlynx Sales Weak, Stock Down Zacks
08:50AM  Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1% Zacks
06:08AM  These 36 Mass. firms made Deloitte's Technology Fast 500 American City Business Journals
Nov-06-19 11:16AM  Don't Sell Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Before You Read This Simply Wall St.
10:56AM  Perrigo (PRGO) Beats on Q3 Earnings, Tightens '19 EPS View Zacks
Nov-05-19 10:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
08:32AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Nov-04-19 05:39PM  Edited Transcript of VRTX earnings conference call or presentation 30-Oct-19 9:00pm GMT Thomson Reuters StreetEvents
Nov-01-19 07:38AM  The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance Benzinga
Oct-31-19 01:12PM  Celgene (CELG) Q3 Earnings Beat, Otezla, Revlimid Sales Rise Zacks
12:33PM  Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates Zacks
12:15PM  Phase 3 Results from Two Studies of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Triple Combination Treatment for Cystic Fibrosis Concurrently Published in The New England Journal of Medicine and The Lancet Business Wire
12:09PM  Vertex Pharmaceuticals Posts Strong 3rd-Quarter Revenue Growth GuruFocus.com
08:08AM  The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut Benzinga
07:21AM  Vertex Announces European Medicines Agency Marketing Authorization Application Validation for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Triple Combination Treatment in Cystic Fibrosis Business Wire
07:07AM  Will Vertex Pharmaceuticals Continue to Surge Higher? Zacks
Oct-30-19 05:15PM  Vertex Pharmaceuticals (VRTX) Beats Q3 Earnings Estimates Zacks
04:55PM  Will The No. 1 Biotech Stock Sacrifice Its Breakout On A Mixed Quarter? Investor's Business Daily
04:01PM  Vertex Reports Third-Quarter 2019 Financial Results Business Wire
12:51PM  Vertex Earnings Beat, Revenue Misses In Q3 Investing.com
10:53AM  Zacks.com featured highlights include: Columbia Sportswear, Boot Barn, Vertex Pharmaceuticals, Upland Software and Spotify Technology Zacks
Oct-29-19 01:00PM  12 Stocks With The Highest Returns On Assets Benzinga
12:17PM  VRTX Keeps Going Vertical Investor's Business Daily Video
09:28AM  Looking for an Earnings Beat? 5 Top Picks Zacks
Oct-28-19 02:58PM  BTIG: Crispr Could Be A Takeover Target For Vertex Benzinga
10:54AM  The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, PulteGroup, Skyworks Solutions, Lennar and Kansas City Southern Zacks
09:39AM  Google Breaks Out, Leading 5 Stocks With $1.8 Trillion Market Cap Near Buy Points Investor's Business Daily
Oct-25-19 12:06PM  Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings? Zacks
09:21AM  Top Ranked Momentum Stocks to Buy for October 25th Zacks
09:20AM  5 Biotech Stocks to Buy for a Strong Growth Prognosis InvestorPlace
07:47AM  5 Top Volatility-Defying S&P 500 Stocks of Past Month Zacks
07:00AM  A Biotech Giant Not Named Biogen Also Had a Good Week Bloomberg
Oct-24-19 02:04PM  Drugs, data and the darknet: Cybersecurity a growing threat in the life sciences American City Business Journals
11:09AM  The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals Zacks
10:50AM  5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3 Zacks
10:39AM  Baxter (BAX) Misses Q3 Revenue Estimates, Issues Guidance Zacks
09:54AM  AstraZeneca (AZN) Q3 Earnings Top, Upgrades '19 Sales View Zacks
09:48AM  UPDATE 1-Vertex cystic fibrosis drug to be available in England after pricing deal Reuters
08:49AM  Cystic fibrosis drug to be available in England after pricing deal Reuters
08:40AM  Factors Setting the Tone for Celgene (CELG) Q3 Earnings Zacks
05:23AM  Vertex Announces Agreement with NHS England for Access to All Licensed Cystic Fibrosis Medicines Business Wire
Oct-23-19 10:34AM  Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth Zacks
10:08AM  ADDING MULTIMEDIA FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation Business Wire
09:45AM  Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates Zacks
Oct-22-19 04:09PM  Vertex Stock Nears Buy Point After Highly Anticipated CF Drug Approved Investor's Business Daily
11:06AM  The Zacks Analyst Blog Highlights: Chipotle Mexican Grill, Vertex Pharmaceuticals, American Electric Power Company, Verizon Communications and V.F. Zacks
10:18AM  What's in Store for IDEXX Laboratories' (IDXX) Q3 Earnings? Zacks
06:39AM  Dow Jones Futures: Stock Market Rally Nears Record Highs; Cadence Design, Vertex, Stamps.com, Opioid Settlement Make News Investor's Business Daily
Oct-21-19 04:07PM  Vertex to Announce Third-Quarter 2019 Financial Results on October 30 Business Wire
03:55PM  FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation Business Wire
03:53PM  UPDATE 2-Vertex prices cystic fibrosis combo treatment at $311,000/yr Reuters
03:16PM  Vertex's drug for almost all cystic fibrosis patients approved five months early American City Business Journals
03:15PM  FDA approves Vertex Pharma's combo treatment for cystic fibrosis Reuters
01:26PM  Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor) Business Wire
10:24AM  Is Walgreens Boots (WBA) Likely to Disappoint in Q4 Earnings? Zacks
09:33AM  Alexion Gets FDA Approval for Label Expansion of Ultomiris Zacks
07:56AM  5 Large-Cap Stocks Set to Beat Earnings Estimates This Month Zacks
Oct-19-19 07:29PM  Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia Business Wire
Oct-18-19 08:54AM  What's in Store for Align Technology's (ALGN) Q3 Earnings? Zacks
08:37AM  Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age Business Wire
Oct-17-19 12:03PM  Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings? Zacks
11:33AM  The Zacks Analyst Blog Highlights: Southern Company, Applied Materials, Vertex Pharmaceuticals, NVIDIA and Edwards Lifesciences Zacks
10:41AM  4 Biotech Stocks That Are Set to Rally, Analyst Says Barrons.com
07:22AM  What's in Store for Edwards Lifesciences' (EW) Q3 Earnings? Zacks
Oct-16-19 02:13PM  Top Research Reports for Southern, Applied Materials & Vertex Zacks
10:33AM  Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? Zacks
10:13AM  CRISPR Therapeutics Enters New License Agreement, Shares Up Zacks
Oct-15-19 10:37AM  Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings? Zacks
Oct-14-19 04:59PM  Selling Tools to Miners: The Stocks That Can Profit on Biotech and Prosthetics GuruFocus.com
11:43AM  Can Balanced Segmental Growth Aid Abbott (ABT) Q3 Earnings? Zacks
10:10AM  Can Vertex (VRTX) Keep the Earnings Surprise Streak Alive? Zacks
09:30AM  Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year? Zacks
Oct-11-19 12:56PM  10 High-Quality, High-Growth Stocks to Buy Kiplinger
Oct-10-19 06:31PM  Were Hedge Funds Right About Dumping Vertex Pharmaceuticals Incorporated (VRTX)? Insider Monkey
Oct-09-19 03:41PM  A Look At The Fair Value Of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Simply Wall St.
Oct-08-19 11:46AM  7 Underpriced Stocks With Biggest Upside as Market Stages 4Q Rally Investopedia
Oct-04-19 09:20AM  Check Out These 5 Fast-Growing Stocks to Buy InvestorPlace
Oct-03-19 11:21AM  Kymera tripling HQ with move out of Cambridge American City Business Journals
Oct-02-19 02:52PM  How a new deal could mean up to $700M for a Durham drugmaker American City Business Journals
09:29AM  Vertex Enters Into Collaboration With Privately-Held Ribometrix Zacks
Oct-01-19 08:00AM  Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer Business Wire
06:31AM  With eyes on IPO, muscular dystrophy startup names new CEO American City Business Journals
Sep-30-19 02:52PM  Investors flee Biotech ETFs as they Lag Bull Market Investopedia
08:00AM  Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics Business Wire
06:21AM  CRISPR gene editing startup Beam Therapeutics plans $100M IPO American City Business Journals
Sep-27-19 09:30AM  Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year? Zacks
Sep-20-19 08:31AM  3 Big Biotech Stocks Worth Adding to Your Portfolio Now Zacks
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; and Kymera Therapeutics, as well as a strategic collaboration with Ribometrix, Inc. to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kewalramani ReshmaEVP and CMONov 08Option Exercise155.5750979,18513,607Nov 13 04:08 PM
Kewalramani ReshmaEVP and CMONov 08Sale199.00509101,29113,098Nov 13 04:08 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 06Option Exercise155.571,223190,26232,776Nov 07 04:36 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 06Sale197.211,223241,18931,553Nov 07 04:36 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 04Option Exercise88.494,126365,11735,679Nov 06 04:10 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 04Option Exercise89.153,708330,57835,395Nov 06 04:11 PM
Parini MichaelEVP, CL&AONov 04Option Exercise86.522,330201,59237,333Nov 06 04:13 PM
Sachdev AmitEVP, Chief Patient OfficerNov 04Option Exercise88.904,097364,23537,513Nov 06 04:15 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 04Sale200.454,126827,04931,553Nov 06 04:10 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 04Sale201.623,708747,60733,240Nov 06 04:11 PM
Parini MichaelEVP, CL&AONov 04Sale200.502,330467,16835,003Nov 06 04:13 PM
Sachdev AmitEVP, Chief Patient OfficerNov 04Sale200.344,097820,79533,416Nov 06 04:15 PM
Bhatia Sangeeta N.DirectorNov 01Option Exercise152.741,291197,1876,540Nov 04 04:11 PM
Kearney Terrence CDirectorNov 01Option Exercise79.1747,4483,756,36725,811Nov 04 04:15 PM
LEIDEN JEFFREY MCEO & PresidentNov 01Option Exercise115.3796,82211,170,756176,577Nov 04 04:13 PM
Bhatia Sangeeta N.DirectorNov 01Sale200.001,291258,2005,249Nov 04 04:11 PM
Kearney Terrence CDirectorNov 01Sale200.0050,60710,121,4005,811Nov 04 04:15 PM
LEIDEN JEFFREY MCEO & PresidentNov 01Sale200.0296,82219,365,992106,287Nov 04 04:13 PM
LEIDEN JEFFREY MCEO & PresidentOct 31Option Exercise131.898,8791,171,051115,166Nov 04 04:13 PM
Kearney Terrence CDirectorOct 31Sale200.001,841368,2008,970Nov 04 04:15 PM
LEIDEN JEFFREY MCEO & PresidentOct 31Sale200.008,8791,775,800106,287Nov 04 04:13 PM
Kewalramani ReshmaEVP and CMOOct 30Option Exercise155.573,057475,57716,155Oct 31 04:36 PM
Kewalramani ReshmaEVP and CMOOct 30Sale199.003,057608,34313,098Oct 31 04:36 PM
Sachdev AmitEVP, Chief Patient OfficerOct 25Option Exercise91.054,311392,51737,727Oct 29 04:54 PM
Sachdev AmitEVP, Chief Patient OfficerOct 25Sale195.014,311840,68833,416Oct 29 04:54 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 22Option Exercise155.573,669570,78635,222Oct 24 07:13 PM
LEIDEN JEFFREY MCEO & PresidentOct 22Option Exercise116.61107,83112,574,276178,707Oct 24 07:23 PM
MCGLYNN MARGARET GDirectorOct 22Option Exercise72.1420,0001,442,80024,124Oct 24 07:26 PM
Sachdev AmitEVP, Chief Patient OfficerOct 22Option Exercise86.523,883335,95737,299Oct 24 07:28 PM
LEIDEN JEFFREY MCEO & PresidentOct 22Sale190.00107,83120,487,890106,287Oct 24 07:23 PM
Kewalramani ReshmaEVP and CMOOct 22Sale189.00638120,58213,098Oct 24 07:18 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 22Sale194.373,669713,14431,553Oct 24 07:13 PM
MCGLYNN MARGARET GDirectorOct 22Sale190.0020,0003,800,0004,124Oct 24 07:26 PM
Sachdev AmitEVP, Chief Patient OfficerOct 22Sale190.273,883738,81833,416Oct 24 07:28 PM
Parini MichaelEVP, CL&AOOct 17Option Exercise122.454,250520,41339,253Oct 21 04:29 PM
Parini MichaelEVP, CL&AOOct 17Sale177.804,250755,65035,003Oct 21 04:29 PM
Parini MichaelEVP, CL&AOOct 14Option Exercise90.292,125191,86637,128Oct 16 04:14 PM
Parini MichaelEVP, CL&AOOct 14Sale174.062,125369,88535,003Oct 16 04:14 PM
Bhatia Sangeeta N.DirectorOct 02Option Exercise126.517,088896,67613,628Oct 04 04:11 PM
Bhatia Sangeeta N.DirectorOct 02Sale166.808,3791,397,6405,249Oct 04 04:11 PM
Tatsis OuraniaSVP, CROOct 02Sale167.6944474,4547,252Oct 03 04:25 PM
Tatsis OuraniaSVP, CROOct 01Sale169.1118831,7937,696Oct 03 04:25 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 19Option Exercise103.2512,5011,290,68136,212Aug 20 04:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 19Sale186.3812,5012,329,97631,553Aug 20 04:30 PM
MCGLYNN MARGARET GDirectorAug 13Option Exercise81.5410,000815,40014,124Aug 15 04:11 PM
MCGLYNN MARGARET GDirectorAug 13Sale185.0010,0001,850,0004,124Aug 15 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 08Option Exercise131.892,125280,26635,365Aug 12 04:14 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 08Sale181.892,125386,51633,240Aug 12 04:14 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 05Option Exercise86.521,553134,36633,793Aug 06 04:41 PM
Parini MichaelEVP, CL&AOAug 05Option Exercise86.522,330201,59237,333Aug 06 04:43 PM
Parini MichaelEVP, CL&AOAug 05Sale175.282,330408,39935,003Aug 06 04:43 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 05Sale176.441,553274,01132,240Aug 06 04:41 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Option Exercise91.052,155196,21334,395Aug 06 04:41 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Sale177.782,155383,11632,240Aug 06 04:41 PM
Parini MichaelEVP, CL&AOJul 12Option Exercise90.292,125191,86637,128Jul 15 04:15 PM
Parini MichaelEVP, CL&AOJul 12Sale175.272,125372,45535,003Jul 15 04:15 PM
Parini MichaelEVP, CL&AOJul 05Option Exercise122.454,250520,41339,253Jul 09 04:49 PM
Parini MichaelEVP, CL&AOJul 05Sale179.114,250761,23935,003Jul 09 04:49 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 19Option Exercise131.892,125280,26635,365Jun 20 04:53 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 19Sale181.892,125386,51633,240Jun 20 04:53 PM
LEIDEN JEFFREY MCEO & PresidentJun 18Option Exercise77.3156,0304,331,679162,317Jun 20 04:43 PM
LEIDEN JEFFREY MCEO & PresidentJun 18Sale175.3956,0309,827,054106,287Jun 20 04:43 PM
Bhatia Sangeeta N.DirectorJun 03Sale167.08720120,2986,540Jun 04 04:08 PM
Parini MichaelEVP, CL&AOMay 30Sale173.00707122,31135,625May 06 04:08 PM
LEIDEN JEFFREY MCEO & PresidentMay 24Option Exercise77.31113,4328,769,428219,719May 28 05:45 PM
LEIDEN JEFFREY MCEO & PresidentMay 24Sale175.10113,43219,861,943106,287May 28 05:45 PM
Sachdev AmitEVP, CROMay 15Sale165.416110,09033,416May 17 04:37 PM
Silva Paul MSVP & ControllerMay 15Sale165.4116126,63117,759May 17 04:31 PM
Parini MichaelEVP, CL&AOMay 15Sale165.418313,72935,003May 17 04:29 PM
Kewalramani ReshmaEVP and CMOMay 15Sale165.4124139,86413,736May 17 04:21 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 15Sale165.4113322,00033,240May 17 04:18 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 15Sale165.419115,05231,553May 17 04:16 PM
LEIDEN JEFFREY MCEO & PresidentMay 06Option Exercise77.3133,0582,555,714136,953May 08 04:10 PM
LEIDEN JEFFREY MCEO & PresidentMay 06Sale175.0133,0585,785,504106,195May 08 04:10 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 03Option Exercise86.521,553134,36634,793May 06 04:06 PM
Parini MichaelEVP, CL&AOMay 03Option Exercise86.522,329201,50537,332May 06 04:08 PM
Parini MichaelEVP, CL&AOMay 03Sale172.061,622279,07435,003May 06 04:08 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 03Sale172.391,553267,72333,240May 06 04:06 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 02Option Exercise91.052,155196,21335,395May 06 04:06 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 02Sale169.272,155364,76833,240May 06 04:06 PM
LEIDEN JEFFREY MCEO & PresidentMay 01Option Exercise77.3110,480810,209116,375May 03 04:06 PM
LEIDEN JEFFREY MCEO & PresidentMay 01Sale175.0810,4801,834,826106,195May 03 04:06 PM
Parini MichaelEVP, CL&AOApr 16Option Exercise111.736,375712,27939,253Apr 18 04:12 PM
Parini MichaelEVP, CL&AOApr 16Sale181.996,3751,160,16635,003Apr 18 04:12 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerApr 15Sale181.755,6241,022,14833,240Apr 17 04:30 PM
LEIDEN JEFFREY MCEO & PresidentFeb 19Sale186.9820,9973,926,113106,195Feb 21 04:24 PM
Kewalramani ReshmaEVP and CMOFeb 19Sale186.941,488278,16313,736Feb 21 04:22 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 19Sale187.005,6241,051,71631,553Feb 21 04:21 PM
Silva Paul MSVP & Interim CFOFeb 19Sale186.972,812525,74717,759Feb 21 04:27 PM
Parini MichaelEVP, CL&AOFeb 19Sale186.985,6241,051,58535,003Feb 21 04:26 PM
LEIDEN JEFFREY MCEO & PresidentFeb 11Sale180.24111,43120,083,804127,192Feb 13 04:39 PM
Sachdev AmitEVP, CROFeb 11Sale180.0635,0956,319,21640,165Feb 13 04:40 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 11Sale180.2232,9565,939,18837,177Feb 13 04:36 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 11Sale180.2133,0735,959,96938,864Feb 13 04:37 PM
Silva Paul MSVP & Interim CFOFeb 11Sale180.164,215759,36720,571Feb 13 04:27 PM
Silva Paul MSVP & Interim CFOFeb 06Option Exercise91.051,289117,36313,938Feb 07 04:04 PM
Silva Paul MSVP & Interim CFOFeb 06Sale193.001,289248,77712,649Feb 07 04:04 PM
Parini MichaelEVP, CL&AOFeb 04Option Exercise86.522,330201,59238,489Feb 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 04Option Exercise88.494,126365,11741,443Feb 06 04:46 PM
Silva Paul MSVP & Interim CFOFeb 04Option Exercise86.5280969,99516,896Feb 06 04:49 PM